Ketamine has been a proven medication for pain relief, and it is often used for administering anesthesia.
Researchers from the Icahn School of Medicine at Mount Sinai found out that people with severe chronic post-traumatic stress disorder can benefit from multiple intravenous ketamine infusions.
The study was published in the American Journal of Psychiatry last September. Researchers agreed that the ketamine infusions would be beneficial to patients with PTSD.
How Ketamine Reduced PTSD Symptoms
Adriana Feder MD, associate professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and lead author of the study, said that their findings on ketamine showed a significant development and benefits for patients.
The researchers have already done the first study on ketamine, and the results were positive when ketamine was infused for 24 hours. It showed a reduction of PTSD symptoms.
In their current study, researchers randomly gave six infusions of ketamine to participants three times for two weeks. The survey participants have severe cases of PTSD from trauma, such as sexual abuse, military, violence, and physical abuse.
The participants went through an evaluation for two weeks. Moreover, they were rated using the Clinician-Administered PTSD Scale for DSM-5 and the Montgomery-Asberg Depression Rating Scale (MADRS)
The participants under the ketamine group manifested at least 30 percent of the reduction in PTSD symptoms.
In the study, the researchers noted that patients have improvements in their moods and depressive symptoms. Furthermore, they suggested that frequent ketamine transfusion is safe and tolerable for PTSD patients.
More Studies for Ketamine and Trauma-Focused Therapy
Dr. Feder and her colleagues are looking into adding the dosage of ketamine and trauma-focused therapy in their study. They are hopeful that they will provide aid to PTSD patients who are struggling with the disease with further investigations and experiments.
The study of Drs. Charney and Feder earned them the NARSAD Independent Investigator Award from the Brain & Behavior Research Foundation (PI Dr. Feder).
A $10 million fund was donated by Mr. Gerald Greenwald and Mrs. Glenda Greenwald and Mount Sinai Innovation Partners through the i3 Accelerator to expedite the research. In addition to this, Ehrenkranz Laboratory of the Depression and Anxiety Discovery and Treatment also supported this project.
The Icahn School of Medicine patented the use of ketamine for PTSD therapy and both Drs. Charney and Feder were named co-investors.
The research is a key step in making ketamine transfusions a solution to improve the lives of people who have PTSD.
Original article posted on fortitudenews.com/health